News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,927 Results
Type
Article (40418)
Company Profile (261)
Press Release (671239)
Multimedia
Podcasts (70)
Webinars (17)
Section
Business (204469)
Career Advice (2016)
Deals (35476)
Drug Delivery (99)
Drug Development (81235)
Employer Resources (173)
FDA (16309)
Job Trends (14915)
News (345904)
Policy (32686)
Tag
Academia (2558)
Accelerated approval (15)
Adcomms (24)
Allergies (112)
Alliances (49572)
ALS (132)
Alzheimer's disease (1549)
Antibody-drug conjugate (ADC) (193)
Approvals (16391)
Artificial intelligence (379)
Autoimmune disease (61)
Automation (25)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (145)
Biotechnology (175)
Bladder cancer (118)
Brain cancer (44)
Breast cancer (452)
Cancer (3587)
Cardiovascular disease (293)
Career advice (1693)
Career pathing (33)
CAR-T (218)
CDC (42)
Cell therapy (588)
Cervical cancer (30)
Clinical research (67862)
Collaboration (1256)
Company closure (4)
Compensation (905)
Complete response letters (42)
COVID-19 (2671)
CRISPR (70)
C-suite (536)
Cystic fibrosis (124)
Data (4215)
Decentralized trials (2)
Denatured (22)
Depression (91)
Diabetes (412)
Diagnostics (6527)
Digital health (32)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (175)
Drug pricing (154)
Drug shortages (28)
Duchenne muscular dystrophy (190)
Earnings (88663)
Editorial (45)
Employer branding (21)
Employer resources (150)
Events (115070)
Executive appointments (916)
FDA (18638)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (13)
Funding (1148)
Gene editing (155)
Generative AI (28)
Gene therapy (468)
GLP-1 (855)
Government (4597)
Grass and pollen (5)
Guidances (336)
Healthcare (18854)
HIV (42)
Huntington's disease (34)
IgA nephropathy (51)
Immunology and inflammation (198)
Immuno-oncology (15)
Indications (52)
Infectious disease (2879)
Inflammatory bowel disease (168)
Inflation Reduction Act (12)
Influenza (85)
Intellectual property (179)
Interviews (314)
IPO (16607)
IRA (48)
Job creations (3639)
Job search strategy (1426)
Kidney cancer (13)
Labor market (69)
Layoffs (531)
Leadership (24)
Legal (7937)
Liver cancer (84)
Longevity (11)
Lung cancer (514)
Lymphoma (255)
Machine learning (27)
Management (59)
Manufacturing (563)
MASH (127)
Medical device (13595)
Medtech (13616)
Mergers & acquisitions (19721)
Metabolic disorders (1009)
Multiple sclerosis (130)
NASH (16)
Neurodegenerative disease (192)
Neuropsychiatric disorders (47)
Neuroscience (2477)
NextGen: Class of 2025 (6516)
Non-profit (4493)
Now hiring (56)
Obesity (474)
Opinion (235)
Ovarian cancer (124)
Pain (145)
Pancreatic cancer (161)
Parkinson's disease (224)
Partnered (27)
Patents (391)
Patient recruitment (294)
Peanut (52)
People (58168)
Pharmaceutical (63)
Pharmacy benefit managers (23)
Phase I (21126)
Phase II (29879)
Phase III (22234)
Pipeline (2611)
Policy (242)
Postmarket research (2564)
Preclinical (8996)
Press Release (64)
Prostate cancer (183)
Psychedelics (42)
Radiopharmaceuticals (256)
Rare diseases (575)
Real estate (5935)
Recruiting (68)
Regulatory (23373)
Reports (51)
Research institute (2347)
Resumes & cover letters (351)
Rett syndrome (15)
RNA editing (11)
RSV (61)
Schizophrenia (120)
Series A (187)
Series B (145)
Service/supplier (11)
Sickle cell disease (72)
Special edition (20)
Spinal muscular atrophy (149)
Sponsored (34)
Startups (3598)
State (2)
Stomach cancer (14)
Supply chain (92)
Tariffs (79)
The Weekly (46)
Vaccines (885)
Venture capital (62)
Weight loss (307)
Women's health (53)
Worklife (17)
Date
Today (98)
Last 7 days (503)
Last 30 days (2267)
Last 365 days (30474)
2025 (23822)
2024 (35218)
2023 (40076)
2022 (51175)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (725)
Alabama (71)
Alaska (7)
Arizona (265)
Arkansas (13)
Asia (38584)
Australia (6303)
California (8980)
Canada (2777)
China (813)
Colorado (379)
Connecticut (385)
Delaware (245)
Europe (83116)
Florida (1345)
Georgia (295)
Hawaii (2)
Idaho (60)
Illinois (701)
India (44)
Indiana (429)
Iowa (17)
Japan (301)
Kansas (117)
Kentucky (33)
Louisiana (16)
Maine (67)
Maryland (1187)
Massachusetts (6584)
Michigan (278)
Minnesota (521)
Mississippi (4)
Missouri (107)
Montana (29)
Nebraska (25)
Nevada (102)
New Hampshire (69)
New Jersey (2469)
New Mexico (28)
New York (2449)
North Carolina (1235)
North Dakota (8)
Northern California (4126)
Ohio (275)
Oklahoma (20)
Oregon (36)
Pennsylvania (1898)
Puerto Rico (18)
Rhode Island (43)
South America (1099)
South Carolina (47)
South Dakota (1)
Southern California (3465)
Tennessee (145)
Texas (1388)
United States (32674)
Utah (268)
Virginia (217)
Washington D.C. (76)
Washington State (753)
West Virginia (4)
Wisconsin (76)
Wyoming (1)
711,927 Results for "lipocine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Lipocine Inc. today announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic (PK) study. Lipocine is developing LPCN 1154, oral brexanolone, for the treatment of postpartum depression (PPD).
June 25, 2024
·
8 min read
Business
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 9, 2024
·
10 min read
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Lipocine Inc. today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154.
May 1, 2024
·
6 min read
Business
Lipocine to Present at 36th Annual Roth Conference
Lipocine Inc. today announced that Dr. Mahesh V. Patel , President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36th Annual Roth Conference.
March 6, 2024
·
3 min read
Business
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Inc. today announced financial results for the year ended December 31, 2023 and provided a corporate update.
March 7, 2024
·
11 min read
Lipocine to Present at Biotech Showcase 2024
Lipocine Inc. today announced that it will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and at a Corporate Access Event organized by LifeSci Partners.
December 19, 2023
·
4 min read
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Lipocine Inc. today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic (PK) study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression (PPD).
February 6, 2024
·
7 min read
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Lipocine Inc. today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154.
March 25, 2024
·
6 min read
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Saturday, June 8, in Milan, Italy.
June 10, 2024
·
7 min read
BioMidwest
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Inc., a biopharmaceutical company, announced results from a Phase 2 clinical trial which includes LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant.
April 11, 2024
·
11 min read
1 of 71,193
Next
